The General Hospital Corporation

Dana-farber-cancer Institute Inc.

Beth Israel Deaconess Medical Center, Inc.

Novartis Ag

The General Hospital Corporation D/b/a Massachusetts General Hospital

Jeffrey Engelman

Pasi Antero Janne

Lewis C Cantley

Matthew J LaMarche

Fang Li

Huaixiang Hao

Hui-Qin Wang

Leila Dardaei Alghalandis

Pasi A Janne

A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.

Methods for treating cancer resistant to ErbB therapeutics

Growing community of inventors

Chestnut Hill, MA, United States of America

Jeffrey Engelman